## M Fernanda Amary

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5605852/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ossifying Fibroma of Non-odontogenic Origin: A Fibro-osseous Lesion in the Craniofacial Skeleton to be (Re-)considered. Head and Neck Pathology, 2022, 16, 257-267.	2.6	9
2	Overlapping morphological, immunohistochemical and genetic features of superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor. Modern Pathology, 2022, 35, 767-776.	5.5	14
3	EWSR1-SMAD3 fibroblastic tumour of bone: expanding the clinical spectrum. Skeletal Radiology, 2021, 50, 445-450.	2.0	4
4	Precocious pseudo-puberty in a 2-year-old girl, presenting with bilateral ovarian enlargement and progressing to unilateral juvenile granulosa cell tumour. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2021, .	0.9	0
5	<scp><i>MYC</i></scp> amplifications are common events in childhood osteosarcoma. Journal of Pathology: Clinical Research, 2021, 7, 425-431.	3.0	12
6	<scp>DNA</scp> methylationâ€based profiling of bone and soft tissue tumours: a validation study of the â€~ <scp>DKFZ</scp> Sarcoma Classifier'. Journal of Pathology: Clinical Research, 2021, 7, 350-360.	3.0	25
7	Benign Bone-Forming Tumors. Surgical Pathology Clinics, 2021, 14, 549-565.	1.7	4
8	<scp>H3K27me3</scp> expression and methylation status in histological variants of malignant peripheral nerve sheath tumours. Journal of Pathology, 2020, 252, 151-164.	4.5	20
9	Drivers underpinning the malignant transformation of giant cell tumour of bone. Journal of Pathology, 2020, 252, 433-440.	4.5	21
10	Sarcoma and the 100,000 Genomes Project: our experience and changes to practice. Journal of Pathology: Clinical Research, 2020, 6, 297-307.	3.0	20
11	Mutational analysis of high-grade spindle cell sarcoma of the femur in Mazabraud's syndrome. Skeletal Radiology, 2019, 48, 151-157.	2.0	5
12	Synovial chondromatosis and soft tissue chondroma: extraosseous cartilaginous tumor defined by FN1 gene rearrangement. Modern Pathology, 2019, 32, 1762-1771.	5.5	67
13	Activating mutations in the MAPâ€kinase pathway define nonâ€ossifying fibroma of bone. Journal of Pathology, 2019, 248, 116-122.	4.5	49
14	Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways. Cancer Cell, 2019, 35, 441-456.e8.	16.8	82
15	FOS Expression in Osteoid Osteoma and Osteoblastoma. American Journal of Surgical Pathology, 2019, 43, 1661-1667.	3.7	50
16	PRDM10-rearranged Soft Tissue Tumor. American Journal of Surgical Pathology, 2019, 43, 504-513.	3.7	35
17	An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. Genes Chromosomes and Cancer, 2019, 58, 88-99.	2.8	67
18	HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee. Journal of Clinical Pathology, 2018, 71, 388-394.	2.0	14

M Fernanda Amary

#	Article	IF	CITATIONS
19	Recurrent rearrangements of FOS and FOSB define osteoblastoma. Nature Communications, 2018, 9, 2150.	12.8	106
20	H3F3A (Histone 3.3) G34W Immunohistochemistry. American Journal of Surgical Pathology, 2017, 41, 1059-1068.	3.7	153
21	Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nature Communications, 2017, 8, 15936.	12.8	179
22	Molecular testing of sarcomas. Diagnostic Histopathology, 2017, 23, 431-441.	0.4	0
23	In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets. Clinical Cancer Research, 2017, 23, 7426-7434.	7.0	73
24	The Chemical Form of Metal Species Released from Corroded Taper Junctions of Hip Implants: Synchrotron Analysis of Patient Tissue. Scientific Reports, 2017, 7, 10952.	3.3	24
25	The driver landscape of sporadic chordoma. Nature Communications, 2017, 8, 890.	12.8	115
26	Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection. Cancer Medicine, 2017, 6, 2194-2202.	2.8	26
27	EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. Journal of Pathology, 2016, 239, 320-334.	4.5	73
28	The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma. Histopathology, 2016, 69, 121-127.	2.9	109
29	Clinical outcome in patients with peripherallyâ€sited atypical lipomatous tumours and dedifferentiated liposarcoma. Journal of Pathology: Clinical Research, 2015, 1, 106-112.	3.0	9
30	Diagnostic value of <i>H3F3A</i> mutations in giant cell tumour of bone compared to osteoclastâ€rich mimics. Journal of Pathology: Clinical Research, 2015, 1, 113-123.	3.0	135
31	Gout-mimicking sarcoma recurrence at a prosthesis bone interface remote from any joint. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 605-607.	1.8	0
32	lsocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 217-222.	2.8	37
33	GNAS mutations are not detected in parosteal and low-grade central osteosarcomas. Modern Pathology, 2015, 28, 1336-1342.	5.5	47
34	Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neoâ€adjuvant chemotherapy. Cancer Medicine, 2014, 3, 980-987.	2.8	57
35	Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nature Genetics, 2014, 46, 376-379.	21.4	269
36	Detection of USP6 gene rearrangement in nodular fasciitis: an important diagnostic tool. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 97-98.	2.8	80

M Fernanda Amary

#	Article	IF	CITATIONS
37	Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nature Genetics, 2013, 45, 923-926.	21.4	180
38	Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma: characterization of five cases. Skeletal Radiology, 2013, 42, 947-957.	2.0	48
39	Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. Nature Communications, 2013, 4, 2166.	12.8	152
40	Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nature Genetics, 2013, 45, 1479-1482.	21.4	667
41	A common single-nucleotide variant in T is strongly associated with chordoma. Nature Genetics, 2012, 44, 1185-1187.	21.4	112
42	<i>IDH1</i> mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas. Histopathology, 2012, 60, 363-365.	2.9	60
43	Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nature Genetics, 2011, 43, 1262-1265.	21.4	368
44	<i>IDH1</i> and <i>IDH2</i> mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. Journal of Pathology, 2011, 224, 334-343.	4.5	834

4